Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 MRI of inflammatory myelitis before and after treatment

Published byFrancisco Javier Pérez Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 MRI of inflammatory myelitis before and after treatment"— Presentation transcript:

1 Figure 1 MRI of inflammatory myelitis before and after treatment
MRI of inflammatory myelitis before and after treatment (A and B) Sagittal and axial T2-weighted images that reveal hyperintensity from C4 to C7 involving the central gray and dorsal white matter bilaterally. T1 post-gadolinium images revealed partial, dorsal enhancement of the lesion with likely pial involvement (C and D) with some involvement of the leptomeninges (arrowhead). Repeat MRI after 2 months of oral prednisone (E–H) shows near resolution of the hyperintense lesion previously extending from C4 to C7, but persistent dorsal enhancement likely indicating a nidus of active granulomatous inflammation. Andrew R. Romeo et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e509 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Download ppt "Figure 1 MRI of inflammatory myelitis before and after treatment"

Similar presentations

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure Cervical spinal cord area assessment

Figure Cervical spinal cord area assessment
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.

Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.

Figure 1 Spine MRI, sagittal and axial views of patients with idiopathic transverse myelitis with VPS37A mutations Spine MRI, sagittal and axial views.
Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.

Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 2 Neurochemical profiles for each neurocognitive trajectory

Figure 2 Neurochemical profiles for each neurocognitive trajectory
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.

Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,

Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,
Figure 1 Quantitative spinal cord MRI maps and segmentations

Figure 1 Quantitative spinal cord MRI maps and segmentations
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Similar presentations

Ads by Google